A Randomized, Open-label, Phase 3 Study of Sacituzumab GovitecanVersus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in theEarly Setting Whose Tumors do Express PD-L1 - Project - Authors - KSSG Research Database

Project

A Randomized, Open-label, Phase 3 Study of Sacituzumab GovitecanVersus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in theEarly Setting Whose Tumors do Express PD-L1

Ongoing - recruitment active · 2022 until 2026

Huober Jens, Scherrer Julia, Quinter Janine

Huober, Jens

chief physician
Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I

Scherrer, Julia

study nurse
Medizinische Onkologie und Hämatologie · Dept. I

Quinter, Janine

Medizinische Onkologie und Hämatologie · Dept. I